167 related articles for article (PubMed ID: 33812985)
1. Ras sumoylation in cell signaling and transformation.
Dai W; Xie S; Chen C; Choi BH
Semin Cancer Biol; 2021 Nov; 76():301-309. PubMed ID: 33812985
[TBL] [Abstract][Full Text] [Related]
2. RAS GTPases are modified by SUMOylation.
Choi BH; Chen C; Philips M; Dai W
Oncotarget; 2018 Jan; 9(4):4440-4450. PubMed ID: 29435114
[TBL] [Abstract][Full Text] [Related]
3. K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion.
Choi BH; Philips MR; Chen Y; Lu L; Dai W
J Biol Chem; 2018 Nov; 293(45):17574-17581. PubMed ID: 30228186
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation.
Kubota Y; O'Grady P; Saito H; Takekawa M
Nat Cell Biol; 2011 Mar; 13(3):282-91. PubMed ID: 21336309
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
6. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.
Qu Y; Chen Q; Lai X; Zhu C; Chen C; Zhao X; Deng R; Xu M; Yuan H; Wang Y; Yu J; Huang J
Mol Cancer; 2014 Apr; 13():95. PubMed ID: 24775912
[TBL] [Abstract][Full Text] [Related]
7. SUMO wrestling with Ras.
Zhang H; Luo J
Small GTPases; 2016 Apr; 7(2):39-46. PubMed ID: 27057691
[TBL] [Abstract][Full Text] [Related]
8. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G; Geiling B; Dankort D
PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo.
Steven A; Heiduk M; Recktenwald CV; Hiebl B; Wickenhauser C; Massa C; Seliger B
Mol Cancer Res; 2015 Aug; 13(8):1248-62. PubMed ID: 25934695
[TBL] [Abstract][Full Text] [Related]
10. Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.
Mazalouskas MD; Godoy-Ruiz R; Weber DJ; Zimmer DB; Honkanen RE; Wadzinski BE
J Biol Chem; 2014 Feb; 289(7):4219-32. PubMed ID: 24371145
[TBL] [Abstract][Full Text] [Related]
11. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
12. An RNAi-based dimorphic genetic screen identified the double bromodomain protein BET-1 as a sumo-dependent attenuator of RAS-mediated signalling.
Gee F; Fisher K; Klemstein U; Poulin GB
PLoS One; 2013; 8(12):e83659. PubMed ID: 24349540
[TBL] [Abstract][Full Text] [Related]
13. Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.
Shields JM; Mehta H; Pruitt K; Der CJ
Mol Cell Biol; 2002 Apr; 22(7):2304-17. PubMed ID: 11884615
[TBL] [Abstract][Full Text] [Related]
14. Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.
Yu B; Swatkoski S; Holly A; Lee LC; Giroux V; Lee CS; Hsu D; Smith JL; Yuen G; Yue J; Ann DK; Simpson RM; Creighton CJ; Figg WD; Gucek M; Luo J
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1724-33. PubMed ID: 25805818
[TBL] [Abstract][Full Text] [Related]
15. Sumoylation and Its Contribution to Cancer.
Lee JS; Choi HJ; Baek SH
Adv Exp Med Biol; 2017; 963():283-298. PubMed ID: 28197919
[TBL] [Abstract][Full Text] [Related]
16. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
18. Isoform-specific Ras signaling is growth factor dependent.
Hood FE; Klinger B; Newlaczyl AU; Sieber A; Dorel M; Oliver SP; Coulson JM; Blüthgen N; Prior IA
Mol Biol Cell; 2019 Apr; 30(9):1108-1117. PubMed ID: 30785867
[TBL] [Abstract][Full Text] [Related]
19. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
[TBL] [Abstract][Full Text] [Related]
20. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
